Literature DB >> 31799645

Long non-coding RNA TUG1 regulates the progression and metastasis of osteosarcoma cells via miR-140-5p/PFN2 axis.

Z-Y Zhao1, Y-C Zhao, W Liu.   

Abstract

OBJECTIVE: Osteosarcoma (OS) is a frequently occurred tumor. Recently, increasing reports disclosed that long non-coding RNA taurine upregulated gene 1 (TUG1) was associated with OS development. Nevertheless, the precise regulatory pattern was not completely understood. Hence, we aimed to investigate the biological role of TUG1 in OS tumorigenesis. PATIENTS AND METHODS: The levels of TUG1, microRNA-140-5p (miR-140-5p), and Profilin 2 (PFN2) were measured via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), and the protein level of PNF2 was assessed using Western blot. In addition, MTT assay was employed to detect the ability of cell proliferation in MG63 and U2OS cells. Cell migration and invasion were estimated adopting transwell assay. Moreover, the Dual-Luciferase reporter assay was performed to verify the interrelation between miR-140-5p and TUG1 or PFN2.
RESULTS: TUG1 and PFN2 levels were evidently upregulated in OS tissues and cell lines. The knockdown of either TUG1 or PFN2 could restrain cell proliferation, migration, and invasion in OS cells. In addition, miR-140-5p was a target of TUG1 to regulate PFN2. The functions of PFN2 knockdown in cell behaviors were rescued after co-transfection with either miR-140-5p inhibitor or overexpression vector of TUG1. Importantly, TUG1 silencing could impede tumor progression in vivo.
CONCLUSIONS: TUG1 modulated cell proliferation, migration, and invasion via miR-140-5p/PFN2 axis in OS progression, which might trigger the development of therapeutic strategies for the treatment of OS.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31799645     DOI: 10.26355/eurrev_201911_19541

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Long non-coding RNA taurine up regulated 1 promotes osteosarcoma cell proliferation and invasion through upregulating Ezrin expression as a competing endogenous RNA of micro RNA-377-3p.

Authors:  Qin Yao; Yingchao Li; Yihua Pei; Bozhen Xie
Journal:  Bioengineered       Date:  2022-01       Impact factor: 3.269

2.  Circ_0008500 Knockdown Improves Radiosensitivity and Inhibits Tumorigenesis in Breast Cancer Through the miR-758-3p/PFN2 Axis.

Authors:  Deyou Kong; Dongxing Shen; Zhikun Liu; Jun Zhang; Jian Zhang; Cuizhi Geng
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-03-03       Impact factor: 2.673

3.  miR-140 inhibits osteosarcoma progression by impairing USP22-mediated LSD1 stabilization and promoting p21 expression.

Authors:  Wei Liu; Dunwei Wang; Lidi Liu; Lin Wang; Ming Yan
Journal:  Mol Ther Nucleic Acids       Date:  2021-02-03       Impact factor: 8.886

4.  The value of lncRNAs as prognostic biomarkers on clinical outcomes in osteosarcoma: a meta-analysis.

Authors:  Wenchao Zhang; Xiaolei Ren; Lin Qi; Chenghao Zhang; Chao Tu; Zhihong Li
Journal:  BMC Cancer       Date:  2021-02-27       Impact factor: 4.430

Review 5.  Role of long noncoding RNA taurine-upregulated gene 1 in cancers.

Authors:  Miao Da; Jing Zhuang; Yani Zhou; Quan Qi; Shuwen Han
Journal:  Mol Med       Date:  2021-05-26       Impact factor: 6.354

Review 6.  MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.

Authors:  Janusz Matuszyk
Journal:  Mol Med       Date:  2022-08-03       Impact factor: 6.376

7.  Impact of miR-1/miR-133 Clustered miRNAs: PFN2 Facilitates Malignant Phenotypes in Head and Neck Squamous Cell Carcinoma.

Authors:  Shunichi Asai; Ayaka Koma; Nijiro Nohata; Takashi Kinoshita; Naoko Kikkawa; Mayuko Kato; Chikashi Minemura; Katsuhiro Uzawa; Toyoyuki Hanazawa; Naohiko Seki
Journal:  Biomedicines       Date:  2022-03-12

8.  miR-1270 enhances the proliferation, migration, and invasion of osteosarcoma <em>via</em> targeting cingulin.

Authors:  Yang Liu; Weichun Guo; Shuo Fang; Bin He; Xiaohai Li; Li Fan
Journal:  Eur J Histochem       Date:  2021-12-07       Impact factor: 3.188

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.